AI Article Synopsis
- The renin-angiotensin-aldosterone system (RAAS) is crucial in managing heart failure with reduced ejection fraction (HFrEF).
- ACE inhibitors are considered the primary treatment for all HFrEF patients, while angiotensin-receptor blockers are alternatives for those who cannot tolerate ACE inhibitors.
- Recent findings suggest that using aldosterone antagonists more widely and combining them with ACE inhibitors is an effective approach for improving symptoms in heart failure patients.
Article Abstract
The renin-angiotensin-aldosterone system (RAAS) plays a critical role in the pathophysiology of heart failure with reduced ejection fraction (HFrEF). Targeting components of the RAAS has produced significant improvements in morbidity and mortality. Angiotensin-converting enzyme (ACE) inhibitors remain first-line therapy for all patients with a reduced ejection fraction. Angiotensin-receptor blockers may be used instead of ACE inhibitors in patients with intolerance, or in conjunction with ACE inhibitors to further reduce symptoms. Recent data support broader indications for aldosterone antagonists in heart failure, and the combination of an ACE-inhibitor and aldosterone antagonist has become the preferred strategy for dual blockade of the RAAS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ccl.2013.09.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!